Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Inclusion Criteria: 1. Females with age between 18 to 70 years old; 2. Histologically confirmed primary invasive breast cancer; 3. Histologically confirmed triple negative breast cancer; 4. Patients who planned to accept preoperative neoadjuvant therapy and had a mass larger than 2 cm. 5. Blood specimens and 5 sections of tumor tissue at baseline, blood specimens at surgery can be obtained. 6. Have at least one measurable lesion as per the RECIST criteria (version 1.1); 7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to one; 8. LVEF≥55%； 9. Bone marrow function：neutrophils (≥1.5×10\^9/L), platelets (≥100×10\^9/L), hemoglobin (≥90 g/L); 10. Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert's syndrome ≤ 2.5 × ULN; 11. Patients had good compliance with the planned treatment, understood the research process and written informed consent. Exclusion Criteria: 1. Previous treatment with any cytotoxic chemotherapy, endocrine therapy, biotherapy or radiotherapy; 2. Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores; 3. Patients with severe systemic infection or other serious diseases; 4. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants; 5. Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer; 6. Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial; 7. Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given; 8. The researchers considered the patients who were not suitable for enrollment.